Matthew Holt

If procurement is understood as getting a better price on something already chosen, involving it during scoping would make no sense.

• By the time the specification, preferred supplier and timeline are fixed, most value has already been decided; what remains is negotiating margin on someone else's decision.
• Procurement is then judged on savings against a baseline it did not set.
• The real question is whether the organisation believes procurement contributes before the point of purchase.
• Otherwise, an earlier invitation just means sitting through a longer meeting.

The post describes the sequence: specification locked, supplier preferred, timeline committed, then procurement called in to negotiate. It closes by asking readers to consider what procurement is understood to do in their organisation.

Read original

The outcome changes if the supplier arrives with two or three genuine questions, asks how the buyer actually decides between suppliers rather than only what they need, follows up within 48 hours with a specific reference to what was said, and resists overselling.

• Restraint signals that the supplier understood the buyer's situation.
• The point is not new marketing material; it is a plan for the conversation.

The post lists these actions directly: questions you need answered, questions about decision criteria, a 48-hour follow-up and less selling. Matthew Holt argues that the strongest signal in a short meeting is usually restraint.

Read original

A polished capability deck tells the buyer what the supplier wants them to know.

• Confidence in that moment signals partnership potential; a scripted deflection reads as exactly that.
• Buyers do not expect weakness-free suppliers; they want suppliers to be honest about weaknesses because that is the version they can work with when something goes wrong.

Matthew Holt contrasts a prepared capability deck with the unscripted five minutes at CPHI Milan. The examples are a capacity constraint, a past delivery miss and an unexpected volume increase.

Read original

Established API manufacturers are building greater supply-chain resilience; growing drug manufacturers are developing procurement functions to support their ambitions; biotech startups need foundational procurement expertise.

• The stated aim is to move pharmaceutical supply chains from firefighting to flow.
• This staged view matters because the same procurement advice does not fit every company: the starting point depends on maturity and immediate risk.

A company update describes onboarding new pharmaceutical clients across the UK, Spain and Italy, naming those three client types. It also describes a roadshow through Malta, Munich, Scotland and Milan, and uses the phrase “from firefighting to flow.”

Read original

That frame connects the diagnostic argument about procurement's role with the practical event advice about honest answers and specific follow-up. The author descriptions and post closings present these values as a stated priority rather than a one-off theme.

The same relationship sentence appears in the closing or bio block of multiple posts, including the procurement-role essay, the CPHI conversation posts and the company update. Matthew Holt also points readers to a monthly newsletter, The Collaborative Source.

Read original · Original 2 · Original 3 · Original 4 · Original 5

The post argues that procurement is usually brought in late because organisations have quietly defined its role as “get us a better price on the thing we’ve already chosen.”

• By the time the specification, supplier preference and timeline are fixed, most of the available value has been decided elsewhere.
• Procurement is left negotiating the margin on someone else’s decision, then judged on savings against a baseline it did not set.
• The post reframes “a seat at the table” as a question of whether the organisation believes procurement contributes before the point of purchase—not whether someone was invited early enough.

For brands planning a campaign

For a co-authored thought-leadership series on procurement’s role in life-science supply chains, this is a ready-made anchor post: it states a clear thesis and invites a named pharma operations leader to respond with where they agree or disagree.

Writing ahead of CPHI Milan, Matthew Holt argues that exhibitors think they are being evaluated on their pitch but are actually judged on how they answer an unscripted question—about a capacity constraint, a past delivery miss or what happens if volume doubles.

• A polished capability deck tells a procurement team what the supplier wants them to know; confidence in the moment signals genuine partnership potential, while a scripted deflection reads as exactly that.
• The post says sponsor procurement is not looking for a supplier with no weaknesses, but one who is honest about them and can be relied on when something goes wrong.

For brands planning a campaign

This could seed a short-form or video piece on “the unscripted five minutes” for a series aimed at pharma suppliers preparing for CPHI or similar events. It also gives the consultancy a concrete, teachable observation to co-author with a procurement lead.

Matthew Holt lists what can change the outcome of a short CPHI meeting: bring two or three questions you genuinely need answered rather than a pitch; ask how the other side actually decides between suppliers, not just what they need; follow up within 48 hours, referencing something specific they said; and resist overselling, because restraint signals you understood their situation. The post’s point is that none of this requires new marketing materials—it requires a plan for the conversation, not just the pitch.

For brands planning a campaign

Useful as a source for a workbook-style resource or checklist the consultancy could co-brand for event preparation. It also offers a direct, practical example of the “teach through specific observations” approach a co-authored series could adopt.

This post describes onboarding new clients across the UK, Spain and Italy over a month: established API manufacturers building supply-chain resilience, growing drug manufacturers developing procurement functions, and biotech startups needing foundational procurement expertise. It frames the consultancy’s purpose as helping transform pharmaceutical supply chains “from firefighting to flow” and shows Matthew Holt and a colleague on a roadshow across Malta, Munich, Scotland and Milan.

For brands planning a campaign

Gives a prospective co-author a concrete view of the client types and geography the consultancy covers. “Firefighting to flow” could work as a series title or recurring motif.

By the time specification, preferred supplier and timeline are locked, most value has already been decided, leaving procurement to negotiate margin on someone else's decision and then be judged on savings against a baseline it did not set. They argue that a seat at the table matters only if the organization believes procurement contributes before the point of purchase; otherwise, an earlier invitation just means a longer meeting.

Frames the issue as an organizational belief problem, then closes with a direct question for readers to apply to their own company.

Ask for a case example, data or a named company where this pattern changed.

For brands planning a campaign

A co-authored series can open with this diagnosis rather than a generic procurement-transformation claim: what procurement is understood to be for, and what would have to change for it to shape scope, supplier choice and timeline.

Examples: Source 1

Matthew Holt advises walking in with two or three questions you genuinely need answered, asking how the other side actually decides between suppliers rather than only what they need, and following up within 48 hours with a reference to something specific they said. The strongest signal in a short meeting, in this view, is restraint: showing you understood the other person's situation rather than running through every capability.

Gives numbered, reusable meeting actions; the longer post contrasts them with a generic pitch, while the event posts show the setting in practice.

Ask for a specific deal or supplier-selection outcome from using this approach.

For brands planning a campaign

Build the co-authored series around a practical event-conversation framework a pharma procurement team can use at CPHI or similar shows. Pair briefing questions and decision-criteria questions with a 48-hour follow-up template.

Examples: Source 1 · Source 2 · Source 3

A polished capability deck says what the supplier wants the buyer to know.

• A confident answer to a difficult question reads as partnership potential; a scripted deflection reads as exactly that.
• Sponsor procurement is not looking for a supplier with no weaknesses, according to the post, but for one who is honest about them because that is the version they will work with when something goes wrong.

Contrasts a prepared deck with an unprepared question and implies a buyer-side evaluation lens rather than a seller-side pitch checklist.

Ask for a transcript, buyer decision record or scoring example to see how this principle is applied.

For brands planning a campaign

A thought-leadership series can explore how suppliers should prepare for the unscripted five minutes at an event, using procurement-side questions that reveal resilience, honesty and problem-solving rather than polished claims.

Examples: Source 1

A company update describes onboarding pharmaceutical clients across the UK, Spain and Italy, including established API manufacturers building greater supply-chain resilience, growing drug manufacturers developing procurement functions to support their ambitions, and biotech startups needing foundational procurement expertise. The stated aim is to help transform pharmaceutical supply chains from firefighting to flow.

Uses client-type examples and the transformation metaphor “firefighting to flow” to show a staged view of procurement need.

Ask for client outcomes and an explanation of how the stages are diagnosed.

For brands planning a campaign

Co-authored content can segment the audience by maturity: foundational procurement for biotech startups, function-building for growing manufacturers, and resilience work for established API manufacturers. Each segment suggests a different article angle and campaign call to action.

Examples: Source 1

The language appears in the bio blocks and connects the diagnostic posts on procurement's role with practical event advice on honest answers and specific follow-up.

The phrase recurs in post closings and author descriptions, making it a stated priority rather than a one-off theme.

Ask for measurable behaviors, governance and examples of failed trust.

For brands planning a campaign

Use this relationship frame as the series' through-line. The co-authored articles can examine what trust and transparency look like in procurement decisions, supplier conversations and post-event follow-up, rather than treating collaboration as a slogan.

Examples: Source 1 · Source 2 · Source 3 · Source 4 · Source 5

Longer pieces, such as the procurement-role and CPHI-conversation posts, build an argument, offer practical actions or questions, then close with Holt's consultancy description and newsletter invitation.

• Shorter posts cover events or company updates, including a CPHI Milan day-two note about the QYOBO breakfast and meetings with pharma companies needing procurement transformation.
• The posts also refer to a monthly newsletter, The Collaborative Source, linked in their featured section.

Long posts use a problem-then-question structure; short posts document events and company news.

Ask for newsletter issues, publication dates and performance data to assess the sequence and reach of these formats.

For brands planning a campaign

A co-authored series could alternate long diagnostic essays with field notes from events or client work, using the newsletter as a recurring channel for the partnership. The format suits a practical framework paired with first-person event observations.

Examples: Source 1 · Source 2 · Source 3 · Source 4 · Source 5

The firm helps API manufacturers build supply-chain resilience, newer drug manufacturers build procurement functions, and biotech startups establish foundational procurement expertise, with recent client work across the UK, Spain, and Italy.

Original disclosure

I'm Matthew Holt, Co-Founder of Collaborative Sourcing - a procurement consultancy dedicated to the life science industries. Our mission is to support companies to improve their bottom-line.

View example

The post shows attendance and a mention of the company; it does not describe a sponsorship, client, or commercial arrangement.

View example

They write about meeting pharma companies with procurement-transformation needs there and about how exhibitors should handle unscripted questions from procurement teams.

View example

Oscar Vega says moving final assembly out of China does not move the underlying supply chain, and procurement should understand where components, tooling and raw materials actually come from.

• Matthew Holt makes a parallel case: procurement adds value only when involved before specifications and suppliers are fixed.
• Follow Oscar Vega for the geographic and tiering side of sourcing risk.

Oscar Vega works at the level of global manufacturing locations, trade flows and cost models such as nearshoring to Mexico and China+1, writing for a broad sourcing audience.

• Matthew Holt focuses on procurement within life-science companies: the function's role, supplier conversations and event behaviour.
• They share an argument-driven style and an instinct for tiering, but their subject matter and industries differ.

Read original · Original 2

Lavine Hemlani's posts on the UAE explain how capital, regulation, manufacturing and genomic data can be coordinated under one owner—a structural argument like Matthew Holt's about where procurement sits in a company's decision sequence.

Lavine Hemlani writes about national strategy, sovereign capital and investment flows in the UAE and the Middle East for founders, investors and industry observers.

• Matthew Holt writes about day-to-day procurement practice inside pharmaceutical and biotech companies for the people running those functions.
• Choose Lavine Hemlani for the macro industry picture and Matthew Holt for changing procurement behaviour on the ground.

Read original · Original 2

Dan Lewis covers manufacturing delivery, automation and digital systems across the facility lifecycle—the operations ground on which Matthew Holt's procurement arguments depend. Read Dan Lewis if your sourcing question is really about what happens after the supplier is chosen.

Dan Lewis mostly summarises industry developments, deals and restructuring news, with periodic opinion on manufacturing execution.

• Matthew Holt builds a sustained argument about procurement and offers reusable advice for meetings and supplier relationships.
• Dan Lewis covers what is happening across the sector; Matthew Holt argues how procurement should work.

Read original · Original 2

Their posts argue that changing a supplier's address does not remove concentration risk, and that procurement should map beyond tier 1 to critical components, tooling, raw materials, and single-source dependencies. This is a better base than Matthew Holt's material for supply-chain strategy leaders weighing footprint and resilience, or for campaigns seeking concrete frameworks for sourcing model design rather than procurement's organisational role.

The tradeoff is a shift in subject and audience.

• Oscar Vega's posts focus on global sourcing and manufacturing locations across industries, not on how a pharma procurement function earns a role in organisational decisions.
• A co-authored series would trade Matthew Holt's diagnosis of procurement's late invitation and advice on supplier conversations for a broader industrial-sourcing lens.
• The co-author or sponsor would need to supply the pharma examples and re-anchor the content in life-science regulation, supplier qualification, and partnership dynamics.
• Their posts also close with a commercial link to a Mexico sourcing site, so the series would need managed promotional framing.

Examples: Source 1 · Source 2

Their posts analyse the UAE's attempt to build capital, regulation, manufacturing, and genomic data under one roof; note that drug discovery is now Mubadala's largest investment sector, ahead of software and fintech; and argue that biotech's bottleneck is everything around the science. This is a better basis for campaigns that position procurement within a larger ecosystem-building story, reach leaders in Gulf biotech investment and policy, or connect sourcing practice to national industrial strategy and capital allocation.

The tradeoff is distance from procurement practice.

• Lavine Hemlani's material focuses on capital allocation, sovereign strategy, and ecosystem design; it does not cover supplier relationship management, sourcing execution, or the buyer-side conversations central to Matthew Holt's strongest posts.
• A co-authored series would shift from how procurement works to why a country might build biotech capacity, with a narrower geographic focus on the UAE.
• The audience would move from pharma procurement and supply-chain leaders to investors and policy-adjacent readers, which may not serve a procurement consultancy's core brief.
• The series would need a strong procurement-specific counterweight to keep its focus on supply-chain decisions rather than investment theses.

Examples: Source 1 · Source 2

Their posts cover industry developments such as licensing deals, regulatory turnover, restructuring, and a top-selling drug milestone.

• They also write about digital manufacturing, automation, CQV, and operational readiness when an acquisition brings automation expertise into a project-delivery platform.
• This is a better fit for campaigns built around frequent, broad updates, sponsors seeking to reach manufacturing, CQV, and project-delivery audiences in life sciences, or series showing how procurement works alongside engineering, quality, and operations in facility and product delivery.

The tradeoff is a thinner argument about procurement's role.

• Dan Lewis's posts mix news aggregation and corporate updates; they do not offer the organisational diagnosis in Matthew Holt's strongest post: procurement is invited late because the organisation has decided its role is to get a better price on something already chosen.
• A co-authored series would trade that focused thesis for breadth and frequency, shifting the reader's task from understanding procurement's standing to keeping up with industry developments.
• The audience would widen beyond procurement leaders to life-sciences manufacturing and operations readers, potentially diluting the campaign's procurement-specific value.
• Each instalment would need a disciplined editorial layer to stay anchored to a procurement decision rather than drift into general industry news.

Examples: Source 1 · Source 2